{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:05:54Z","timestamp":1790438754847,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.blre.2020.100792","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T18:58:23Z","timestamp":1609009103000},"page":"100792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions"],"prefix":"10.1016","volume":"48","author":[{"given":"Nuria","family":"Martinez-Cibrian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Perez-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"694","key":"10.1016\/j.blre.2020.100792_bb0005","first-page":"439","article-title":"Quantitative studies on tissue transplantation immunity: induction of tolerance in newborn mice and studies on the phenomenon of runt disease","volume":"242","author":"Billinghan","year":"1959","journal-title":"Philos Trans R Soc Lond A"},{"key":"10.1016\/j.blre.2020.100792_bb0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V19.2.217.217","article-title":"Marrow transplants in lethally irradiated dogs given methotrexate","volume":"19","author":"Thomas","year":"1962","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V36.4.507.507","article-title":"Technique for human marrow grafting","volume":"36","author":"Thomas","year":"1970","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2020.100792_bb0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100792_bb0025","series-title":"Thomas\u2019 Hematopoietic Cell Transplantation","first-page":"353","article-title":"The pathophysiology of graft-vs.-host disease","author":"Ferrara","year":"2004"},{"issue":"22","key":"10.1016\/j.blre.2020.100792_bb0030","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2020.100792_bb0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2014-02-514745","article-title":"The biology of graft-versus-host disease: experimental systems instructing clinical practice","volume":"124","author":"Markey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100792_bb0040","article-title":"New insights into the basic biology of acute-graft versus-host-disease","author":"Li","year":"2020","journal-title":"Haematologica"},{"issue":"5426","key":"10.1016\/j.blre.2020.100792_bb0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.285.5426.412","article-title":"Prevention of graft versus host disease by inactivation of host antigen-presenting cells","volume":"285","author":"Schlomchik","year":"1999","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.it.2004.04.006","article-title":"Yin-Yang regulation of autoimmunity by DCs","volume":"25","author":"Hart","year":"2004","journal-title":"Trends Immunol"},{"issue":"11","key":"10.1016\/j.blre.2020.100792_bb0055","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2004-12-4726","article-title":"Leukocyte migration and graft-versus-host disease","volume":"105","author":"Wysocki","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2020.100792_bb0060","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJM199212033272301","article-title":"Host specific interleukin-2 secreting donor T cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings","volume":"327","author":"Theobald","year":"1992","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2020.100792_bb0065","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.V95.9.2754.009k25_2754_2759","article-title":"The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokines shileds in allogeneic bone marrow transplantation","volume":"95","author":"Hill","year":"2000","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.blre.2020.100792_bb0070","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood.2019000823","article-title":"The primacy of gastrointestinal tract antigen-presenting cells in lethal graft-versus-host disease","volume":"134","author":"Koyama","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.blre.2020.100792_bb0075","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2020.100792_bb0080","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0301-472X(03)00190-5","article-title":"Minor histocompatibility antigens in human stem cell transplantation","volume":"31","author":"Falkenburg","year":"2003","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0085","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0092-8674(94)90334-4","article-title":"Signal transduction by lymphocyte antigen receptors","volume":"76","author":"Weiss","year":"1994","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.blre.2020.100792_bb0090","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0952-7915(02)00339-4","article-title":"The T-cell receptor signalosome: a dynamic structure with expanding complexity","volume":"14","author":"Werlen","year":"2002","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.blre.2020.100792_bb0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","article-title":"T cell activation","volume":"27","author":"Smith-Garvin","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"26","key":"10.1016\/j.blre.2020.100792_bb0100","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0105","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","article-title":"Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age","volume":"98","author":"Kollman","year":"2001","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2020.100792_bb0110","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2020.100792_bb0120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.blre.2020.100792_bb0125","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0130","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V80.7.1838.1838","article-title":"Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate","volume":"80","author":"Nash","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100792_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1703616","article-title":"Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease","volume":"30","author":"Kumar","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2020.100792_bb0140","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood.V88.11.4383.4383","article-title":"Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation","volume":"88","author":"Przepiorka","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0145","first-page":"CD010280","article-title":"Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Kharfan-Dabaja","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0150","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2007-06-094482","article-title":"Differential impact of mTOR inhibition on CD4+CD25+Foxp3+ regulatory T cells as compared to conventional CD4+ T cells","volume":"111","author":"Zeiser","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2020.100792_bb0160","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2020.100792_bb0165","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.bbmt.2015.07.010","article-title":"CD34-selected hematopoietic stem cell transplants conditioned with myeloablative regimens and antithymocyte globulin for advanced myelodysplastic syndrome: limited graft-versus-host disease without increased relapse","volume":"21","author":"Tamari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbmt.2012.09.003","article-title":"T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease","volume":"19","author":"Goldberg","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.blre.2020.100792_bb0175","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/bmt.2009.371","article-title":"Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT","volume":"45","author":"Perales","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.blre.2020.100792_bb0180","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2007-06-093880","article-title":"T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin","volume":"110","author":"Jakubowski","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2020.100792_bb0185","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.bbmt.2013.02.018","article-title":"Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0190","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/bmt.2014.302","article-title":"Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts","volume":"50","author":"Hobbs","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2020.100792_bb0195","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bbmt.2018.01.001","article-title":"Allogeneic stem cell transplantation for advanced myelodysplastic syndrome: comparison of outcomes between CD34(+) selected or unmodified hematopoietic stem cells transplants","volume":"24","author":"Tamari","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2020.100792_bb0200","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.bbmt.2017.12.804","article-title":"CD34+ selection vs. reduced-intensity conditioning and unmodified graft for allogeneic hematopoietic cell transplantation in patients with AML and MDS > 50 years","volume":"24","author":"Barba","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0205","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.1999.17.2.561","article-title":"Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion","volume":"17","author":"Sehn","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0210","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.blre.2020.100792_bb0215","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100792_bb0220","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3324\/haematol.2011.059378","article-title":"Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3\/CD19 depletion and reduced intensity conditioning: a phase II study","volume":"97","author":"Federmann","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2020.100792_bb0225","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41409-019-0550-0","article-title":"Haploidentical CD3 or \u03b1\/\u03b2 T-cell depleted HSCT in advanced stage sickle cell disease","volume":"54","author":"Foell","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2020.100792_bb0230","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.bbmt.2019.01.023","article-title":"\u03b1\u03b2 T cell-depleted haploidentical hematopoietic stem cell transplantation without antithymocyte globulin in children with chemorefractory acute myelogenous leukemia","volume":"25","author":"Shelikhova","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0235","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0240","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2020.100792_bb0245","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0255","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.blre.2020.100792_bb0260","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2020.100792_bb0265","first-page":"CD009159","article-title":"Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults","volume":"12","author":"Theurich","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0270","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100792_bb0275","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.2009.008649","article-title":"Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission","volume":"94","author":"Patel","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2020.100792_bb0280","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","article-title":"Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders","volume":"100","author":"P\u00e9rez-Sim\u00f3n","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0285","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0290","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00007890-198610000-00018","article-title":"Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients","volume":"42","author":"Mayumi","year":"1986","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.blre.2020.100792_bb0295","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0300","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"28","key":"10.1016\/j.blre.2020.100792_bb0305","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2020.100792_bb0310","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","article-title":"Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide","volume":"129","author":"Kanakry","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100792_bb0315","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100792_bb0320","first-page":"1","article-title":"Results of the prospective randomized HOVON-96 trial in recipients of matched related and unrelated donors","volume":"134","author":"Broers","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0325","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"Practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol Rev"},{"issue":"9","key":"10.1016\/j.blre.2020.100792_bb0330","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0335","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3324\/haematol.2008.005017","article-title":"Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population","volume":"94","author":"Blanco","year":"2009","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.blre.2020.100792_bb0340","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.leukres.2011.05.018","article-title":"Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens","volume":"35","author":"Blanco","year":"2011","journal-title":"Leuk Res"},{"issue":"26","key":"10.1016\/j.blre.2020.100792_bb0345","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.blre.2020.100792_bb0350","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbmt.2015.05.027","article-title":"A bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in myeloablative HLA-mismatched and unrelated donor transplantation: a phase II trial","volume":"21","author":"Koreth","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.blre.2020.100792_bb0355","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3324\/haematol.2017.176859","article-title":"Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results","volume":"103","author":"Koreth","year":"2018","journal-title":"Haematologica"},{"issue":"2S Suppl 1","key":"10.1016\/j.blre.2020.100792_bb0360","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/TP.0000000000001806","article-title":"mTOR inhibition role in cellular mechanisms","volume":"102","author":"Zaza","year":"2018","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0365","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13931","article-title":"The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2020.100792_bb0370","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0375","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.blre.2020.100792_bb0380","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","article-title":"Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation","volume":"112","author":"Cutler","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2020.100792_bb0385","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2020.100792_bb0390","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3324\/haematol.2012.067140","article-title":"A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation","volume":"97","author":"Pidala","year":"2012","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.blre.2020.100792_bb0395","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1182\/blood-2013-10-534297","article-title":"The addition of sirolimus to tacrolimus\/methotrexate GVHD prophylaxis in children with ALL: a phase 3 children\u2019s oncology group\/pediatric blood and marrow transplant consortium trial","volume":"123","author":"Pulsipher","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100792_bb0400","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2013.09.003","article-title":"In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial","volume":"19","author":"Koura","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100792_bb0405","first-page":"212","article-title":"T cell coestimulation blockade with abatacept nearly eliminates early severe acute graft versus host disease after HLA-mismtached (7\/8 HLA matched) unrelated donor transplant, with a favourable impact on disease-free and overall survival","volume":"130","author":"Watkins","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100792_bb0410","series-title":"TCT Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR, Houston, Texas, USA","article-title":"T cell costimulation blockade with CTLA4-ig (abatacept) for acute GvHD prevention in HLA matched and mismatched unrelated donor transplantation: results of the first phase 2 trial","author":"Watkins","year":"2019"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0415","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1189\/jlb.0306231","article-title":"Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects","volume":"81","author":"Ueha","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0420","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2005-08-3445","article-title":"Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine","volume":"107","author":"Waldman","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2020.100792_bb0425","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/bloodadvances.2019000893","article-title":"Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Chen","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0430","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1172\/JCI6642","article-title":"Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease","volume":"104","author":"Murai","year":"1999","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0435","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ni879","article-title":"Peyer\u2019s patch is the essential site in initiating murine acute and lethal graft-versus-host reaction","volume":"4","author":"Murai","year":"2003","journal-title":"Nat Immunol"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0440","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4049\/jimmunol.173.2.845","article-title":"Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning","volume":"173","author":"Wysocki","year":"2004","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0445","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1201248","article-title":"Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease","volume":"367","author":"Reshef","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0450","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood-2016-08-735076","article-title":"Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis","volume":"129","author":"Moy","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100792_bb0455","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbmt.2018.09.034","article-title":"Extended CCR5 blockade for graft-versus-host disease prophylaxis improves outcomes of reduced-intensity unrelated donor hematopoietic cell transplantation: a phase II clinical trial","volume":"25","author":"Reshef","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0460","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","article-title":"Blockade of interleukin 6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2020.100792_bb0465","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1470-2045(14)71017-4","article-title":"Addition of interleukin 6 inhibition with tocilizumab to standard graft versus host disease prophylaxis after allogeneic stem cell transplantation: a phase 1\/2 trial","volume":"15","author":"Kennedy","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0470","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2017.183434","article-title":"Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of low gastrointestinal tract disease","volume":"103","author":"Drobyski","year":"2019","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2020.100792_bb0475","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2019-126285","article-title":"Results of a phase III double-blind study of the addition of tocilizumab vs placebo to cyclosporine\/methotrexate GVHD prophylaxis after HLA-matched allogeneic stem cell transplantation","volume":"134","author":"Kennedy","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2020.100792_bb0480","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2002-03-0985","article-title":"Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation","volume":"100","author":"Antin","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0485","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.bbmt.2008.04.006","article-title":"Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation","volume":"14","author":"Hamadami","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.blre.2020.100792_bb0490","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.bbmt.2012.03.013","article-title":"TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFRI levels correlate with better outcomes","volume":"18","author":"Choi","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2020.100792_bb0495","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbmt.2015.11.002","article-title":"Combination therapy for graft-versus-host disease prophylaxis with etanercept and extracorporeal photopheresis: results of a phase II clinical trial","volume":"22","author":"Kitko","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2020.100792_bb0500","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1074-7613(00)80642-1","article-title":"Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation","volume":"9","author":"Agarwal","year":"1998","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.blre.2020.100792_bb0505","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1074-7613(02)00314-X","article-title":"Th2 lineage commitment and efficient IL-4 production involves extended demethylation of the IL-4 gene","volume":"16","author":"Lee","year":"2002","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.blre.2020.100792_bb0510","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.4049\/jimmunol.153.8.3603","article-title":"Differentiation of the T helper phenotypes by analysis of the methylation state of the IFN-\u03b3 gene","volume":"153","author":"Young","year":"1994","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0515","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ni808","article-title":"TH cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes","volume":"3","author":"Avni","year":"2002","journal-title":"Nat Immunol"},{"issue":"5609","key":"10.1016\/j.blre.2020.100792_bb0520","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0525","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nri2474","article-title":"Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?","volume":"9","author":"Huehn","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0530","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"S\u00e1nchez-Abarca","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100792_bb0535","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/nm1107-1282","article-title":"Blocking HDACs boosts regulatory T cells","volume":"13","author":"Reddy","year":"2007","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.blre.2020.100792_bb0540","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.blre.2020.100792_bb0545","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","article-title":"Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Choi","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.blre.2020.100792_bb0550","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2017-06-790469","article-title":"Vorinostat plus tacrolimus\/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT","volume":"130","author":"Choi","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100792_bb0555","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V96.7.2391","article-title":"Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study","volume":"96","author":"Ruutu","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100792_bb0560","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/cncr.31100","article-title":"A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: improved long-term survival with triple prophylaxis","volume":"124","author":"Ruutu","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2020.100792_bb0565","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1242\/dmm.006668","article-title":"Mouse models of graft versus-host disease: advances and limitations","volume":"4","author":"Schroeder","year":"2011","journal-title":"Dis Model Mech"},{"issue":"9823","key":"10.1016\/j.blre.2020.100792_bb0570","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2020.100792_bb0575","first-page":"1(1)","article-title":"Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition","author":"Fisher","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.blre.2020.100792_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100669","article-title":"Can we preventor treat graft-versus-host disease with cellular-therapy?","author":"Zahid","year":"2020","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0585","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.blre.2020.100792_bb0590","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2020.100792_bb0595","doi-asserted-by":"crossref","first-page":"102944","DOI":"10.1016\/j.critrevonc.2020.102944","article-title":"Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: a multiple-treatments network meta-analysis","volume":"150","author":"Xin Lv","year":"2020","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20301429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20301429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:24Z","timestamp":1759436904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20301429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":119,"alternative-id":["S0268960X20301429"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100792","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100792"}}